Prospective Validation of CARPET Prognostic Model for Septic Shock After Allo-HSCT
NCT ID: NCT06022445
Last Updated: 2023-09-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
200 participants
OBSERVATIONAL
2023-09-01
2024-12-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study on the Construction and Application of Early Warning Model of Sepsis in Critically Ill Patients
NCT06904001
Nasal and Gut Microbiota Combined Clinical Events Predicts the Prognosis of Septic Patients
NCT05143736
Establishment of Early Diagnosis and Monitoring Model for Sepsis Patients
NCT04974411
Extracorporeal Cytokine Removal in Patients With Septic Shock in an Adult Intensive Care Unit
NCT04231695
Prolonged Intravenous Infusion of β-lactam Antibiotics in Early Septic Patients
NCT05024565
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The equation of the prediction model for 28-day mortality was as follows:
Probability(28-day mortality)=(exp(Y))/(1+exp(Y)) where Y=2.343+1.328\* Time of septic shock- 0.085\* Albumin + 0.016 \* Bilirubin-0.003\*PaO2/FiO2 +0.127\*Lactate- 0.011 \* Glomerular filtration rate
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients with septic shock after allo-HSCT
patients who underwent allo-HSCT and experienced septic shock
CARPET prognostic model
For patients diagnosed with septic shock, we obtained the information in CARPET prognostic model including time of septic shock, albumin, bilirubin, PaO2/FiO2, lactate, and GFR. We calculated the CARPET risk score and the 28-day mortality probability according to CARPET logistic regression model.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
CARPET prognostic model
For patients diagnosed with septic shock, we obtained the information in CARPET prognostic model including time of septic shock, albumin, bilirubin, PaO2/FiO2, lactate, and GFR. We calculated the CARPET risk score and the 28-day mortality probability according to CARPET logistic regression model.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* underwent allo-HSCT
* diagnosed with septic shock
Exclusion Criteria
* relapsed or progressed after HSCT
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Navy General Hospital, Beijing
OTHER
Second Hospital of Shanxi Medical University
OTHER
The Second Hospital of Hebei Medical University
OTHER
Shanghai Zhongshan Hospital
OTHER
Shanxi Dayi Hospital
OTHER
People's Hospital of Xinjiang Uygur Autonomous Region
OTHER
Guangzhou University of Chinese Medicine
OTHER
The First Affiliated Hospital of Zhengzhou University
OTHER
Peking Union Medical College
OTHER
First Affiliated Hospital of Harbin Medical University
OTHER
Peking University People's Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Xiao Hui Zhang
Vice president of Peking University Institute of Hematology
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Xiaohui Zhang, MD
Role: PRINCIPAL_INVESTIGATOR
Peking University Insititute of Hematology, Peking University People's Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Peking University Insititute of Hematology, Peking University People's Hospital
Beijing, Beijing Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PKUPH-model validation
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.